A little less than a year ago I posted on the FDA's new proposed rule on off label marketing:
I said then it was a rotten idea. Apparently the FDA agreed as they are now rushing to slip the rule into force during the last days of the outgoing Bush Administration:
Presumably the only way to get this measure through was to speed it up before the Obama people rolled into town with their generally less-compliant attitude toward the large dug companies. The measure primarily addresses giving docs reprints of medical journal articles that describe off-label uses of a medication. (See my previous post on why I thought the rule was generally misguided.)
The FDA claims that these rules tighten up the process because they discourage ghostwriting. How do they discourage it? Well, the rules recommend that companies disclose any financial relationships between them and an article's authors. Yeah, I am sure that will be a water-tight safeguard.